- Home
- BCLI vs MBRX Comparison
BCLI vs MBRX Comparison
Compare BCLI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- MBRX
- Stock Information
- Founded
- BCLI 2000
- MBRX 2015
- Country
- BCLI United States
- MBRX United States
- Employees
- BCLI N/A
- MBRX N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- MBRX Health Care
- Exchange
- BCLI Nasdaq
- MBRX Nasdaq
- Market Cap
- BCLI 6.4M
- MBRX 7.7M
- IPO Year
- BCLI N/A
- MBRX 2016
- Fundamental
- Price
- BCLI $1.21
- MBRX $2.70
- Analyst Decision
- BCLI Strong Buy
- MBRX Strong Buy
- Analyst Count
- BCLI 1
- MBRX 3
- Target Price
- BCLI $30.00
- MBRX $31.00
- AVG Volume (30 Days)
- BCLI 118.2K
- MBRX 54.8K
- Earning Date
- BCLI 11-14-2024
- MBRX 11-08-2024
- Dividend Yield
- BCLI N/A
- MBRX N/A
- EPS Growth
- BCLI N/A
- MBRX N/A
- EPS
- BCLI N/A
- MBRX N/A
- Revenue
- BCLI N/A
- MBRX N/A
- Revenue This Year
- BCLI N/A
- MBRX N/A
- Revenue Next Year
- BCLI N/A
- MBRX N/A
- P/E Ratio
- BCLI N/A
- MBRX N/A
- Revenue Growth
- BCLI N/A
- MBRX N/A
- 52 Week Low
- BCLI $1.05
- MBRX $0.40
- 52 Week High
- BCLI $11.85
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- BCLI 23.69
- MBRX 53.82
- Support Level
- BCLI $1.05
- MBRX $2.50
- Resistance Level
- BCLI $1.95
- MBRX $3.33
- Average True Range (ATR)
- BCLI 0.20
- MBRX 0.24
- MACD
- BCLI -0.00
- MBRX 0.04
- Stochastic Oscillator
- BCLI 15.84
- MBRX 39.42
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.